Which is better, LMAT or ZTS?

On the Buffett-Fit framework, LeMaitre Vascular, Inc. (LMAT) currently grades higher than ZTS — 77/100 (B grade) vs 64/100 (C). That said, "better" depends on which framework you trust — LMAT wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, and Joel Greenblatt; ZTS wins on Charlie Munger and Terry Smith. The full pillar breakdown is on this page.

Should I buy LMAT or ZTS?

This page is an educational comparison, not investment advice. Both LMAT and ZTS are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is LMAT better than ZTS for value investing?

On the Buffett-style value-investing framework, LMAT currently grades higher — 77/100 vs 64/100, a 13-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between LMAT and ZTS on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). LMAT currently scores 77/100 (B grade); ZTS scores 64/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, LMAT or ZTS?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. LMAT and ZTS are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, LMAT or ZTS?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are LMAT and ZTS both Healthcare stocks?

Yes — both LeMaitre Vascular, Inc. (LMAT) and Zoetis Inc. (ZTS) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this LMAT vs ZTS comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

LeMaitre Vascular

Zoetis

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

ZTS

Zoetis

Market cap

$34.09B

Sector

Healthcare

Overall winner

LeMaitre Vascular LMAT

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	LMAT	ZTS	Winner
Warren Buffett	77B	64C	LMAT
Benjamin Graham	89A	70B	LMAT
Philip Fisher	81C	61C	LMAT
Peter Lynch	67B	42D	LMAT
Joel Greenblatt	56D	43D	LMAT
Charlie Munger	68D	69B	ZTS
Terry Smith	69D	73B	ZTS

Side-by-side metrics

Metric	LMAT	ZTS
Market cap	$2.23B	$34.09B
P/E (TTM)	37.1x	11.9x
EV/EBIT	36.6x	10.8x
ROIC (TTM)	9.43%	21.79%
Gross margin	72.39%	70.75%
Net margin	24.35%	27.79%
Revenue CAGR 5y	12.75%	5.04%
EPS CAGR 5y	19.04%	8.88%
Debt / Equity	0.5x	0.1x
Dividend yield	0.84%	2.77%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LMAT leads on

Revenue CAGR 5y12.75%vs 5.04%+60%
EPS CAGR 5y19.04%vs 8.88%+53%

ZTS leads on

Market cap$34.09Bvs $2.23B+93%
Debt / Equity0.1xvs 0.5x+87%
EV/EBIT10.8xvs 36.6x+70%
Dividend yield2.77%vs 0.84%+70%

More like LMAT

LMAT vs IDXX LMAT vs 7741.T LMAT vs GMAB LMAT vs HALO LMAT vs SUNPHARMA.NS LMAT vs MTD

More like ZTS

ZTS vs IDXX ZTS vs 7741.T ZTS vs GMAB ZTS vs HALO ZTS vs SUNPHARMA.NS ZTS vs MTD

Read the full Buffett-Brain analysis for LMAT Read the full Buffett-Brain analysis for ZTS

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

LeMaitre Vascular

Zoetis

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

ZTS

Zoetis

Market cap

$34.09B

Sector

Healthcare

Overall winner

LeMaitre Vascular LMAT

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	LMAT	ZTS	Winner
Warren Buffett	77B	64C	LMAT
Benjamin Graham	89A	70B	LMAT
Philip Fisher	81C	61C	LMAT
Peter Lynch	67B	42D	LMAT
Joel Greenblatt	56D	43D	LMAT
Charlie Munger	68D	69B	ZTS
Terry Smith	69D	73B	ZTS

Side-by-side metrics

Metric	LMAT	ZTS
Market cap	$2.23B	$34.09B
P/E (TTM)	37.1x	11.9x
EV/EBIT	36.6x	10.8x
ROIC (TTM)	9.43%	21.79%
Gross margin	72.39%	70.75%
Net margin	24.35%	27.79%
Revenue CAGR 5y	12.75%	5.04%
EPS CAGR 5y	19.04%	8.88%
Debt / Equity	0.5x	0.1x
Dividend yield	0.84%	2.77%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LMAT leads on

Revenue CAGR 5y12.75%vs 5.04%+60%
EPS CAGR 5y19.04%vs 8.88%+53%

ZTS leads on

Market cap$34.09Bvs $2.23B+93%
Debt / Equity0.1xvs 0.5x+87%
EV/EBIT10.8xvs 36.6x+70%
Dividend yield2.77%vs 0.84%+70%

More like LMAT

LMAT vs IDXX LMAT vs 7741.T LMAT vs GMAB LMAT vs HALO LMAT vs SUNPHARMA.NS LMAT vs MTD

More like ZTS

ZTS vs IDXX ZTS vs 7741.T ZTS vs GMAB ZTS vs HALO ZTS vs SUNPHARMA.NS ZTS vs MTD

Read the full Buffett-Brain analysis for LMAT Read the full Buffett-Brain analysis for ZTS

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.